FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
11 Febbraio 2020
Kite, a Gilead Company has announced that the U.S. Food and Drug Administration has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19,
